Seastar Medical Hldg Corp (ICU)

$2.45 -0.07 (-2.78%)
Market Cap 9.02M
Revenue (ttm) 140,000.00
Net Income (ttm) -24.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -17,735.71%
Debt to Equity Ratio 0.00
Volume 67,900
Avg Vol 212,256
Day's Range N/A - N/A
Shares Out 3.79M
Stochastic %K 41%
Beta -1.00
Analysts Strong Sell
Price Target $11.00

Company Profile

SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI)...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 427 8100
Address:
3513 Brighton Boulevard, Suite 410, Denver, United States
HuntingBenjmins
HuntingBenjmins Feb. 4 at 5:30 AM
$ICU Allright…who gave Nikki the fruit loops with sugar on them?
0 · Reply
josh77
josh77 Feb. 4 at 4:38 AM
$ICU 5. Expanded Indications If ICU announces that its technology can be applied to additional patient groups or conditions, the market size grows — and so does investor interest. 6. Real‑World Hospital Use Positive case studies or early adoption by hospitals could provide real‑world proof that the device works and has value.
0 · Reply
josh77
josh77 Feb. 4 at 4:38 AM
$ICU Catalysts for ICU This version digs deeper into what actually could move the stock. Detailed Catalyst Breakdown: For ICU, the most realistic catalysts fall into a few key categories: 1. Clinical Data Updates Any positive results from ongoing or upcoming studies would be the strongest catalyst. Even early‑stage improvements in safety or efficacy could shift sentiment. 2. FDA or Regulatory Progress If the company receives: acceptance of a submission Fast Track designation positive feedback from a regulatory meeting …that would immediately strengthen the outlook. 3. Strategic Partnerships A collaboration with a larger medical device or biotech company would: validate the technology bring in resources reduce financial pressure This is one of the most powerful potential catalysts. 4. Funding or Cash‑Runway Improvements Non‑dilutive funding, grants, or institutional investment would ease concerns about survival and delisting.
0 · Reply
josh77
josh77 Feb. 4 at 4:25 AM
$ICU If they can deliver positive clinical updates, secure a partnership, or make progress with the FDA, the sentiment could change quickly. Even stabilizing their finances or expanding indications would help. It’s definitely a high‑risk play, but in this sector, momentum can flip fast when the right pieces fall into place. I’m just watching for those potential catalysts and staying patient.
0 · Reply
Brad_7424
Brad_7424 Feb. 4 at 2:32 AM
$ICU Folks, this it was severe delusion looks like. $45 per share, yet their last announced revenue wasn't even enough to pay its staff a salary💀 This will go below 1 again and have another RS at the end of this year or early 2027. You might get lucky trading this short term, but that's gambling, not investing.
0 · Reply
hardgrandpa
hardgrandpa Feb. 4 at 1:02 AM
$ICU
0 · Reply
Yi_YandH
Yi_YandH Feb. 3 at 11:41 PM
$ICU When the pissants piss, Ich hüpfen vor freude!!!
0 · Reply
Nikki7220
Nikki7220 Feb. 3 at 11:13 PM
$ICU ***** Whatever you think, ICU does NOT have manpower to move SCD. Worst they NEVER know how to market SCD. They are so WEAK. Presentations to financial people so many times NOT attracting meaningful investors.
1 · Reply
techjerk
techjerk Feb. 3 at 10:54 PM
$ICU Who says a pessimist can't pump lol
0 · Reply
techjerk
techjerk Feb. 3 at 10:53 PM
$ICU Regulatory & Partnership News: Potential announcements regarding additional Breakthrough Device Designations or Humanitarian Use Designations to speed up commercialization in other indications, such as Cardio-Renal Syndrome.
0 · Reply
Latest News on ICU
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference

Jan 29, 2026, 8:25 AM EST - 5 days ago

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference

SeaStar Medical Announces 2026 Milestones

Jan 7, 2026, 8:13 AM EST - 27 days ago

SeaStar Medical Announces 2026 Milestones

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference

Jan 6, 2026, 8:53 AM EST - 4 weeks ago

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference

SeaStar Medical Announces 1-for-10 Reverse Split

Dec 23, 2025, 4:25 PM EST - 6 weeks ago

SeaStar Medical Announces 1-for-10 Reverse Split

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

Dec 2, 2025, 8:27 AM EST - 2 months ago

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

Nov 20, 2025, 9:52 AM EST - 2 months ago

SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

SeaStar Medical Announces Appointment of Michael Messinger as CFO

Nov 17, 2025, 8:43 AM EST - 2 months ago

SeaStar Medical Announces Appointment of Michael Messinger as CFO

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 13, 2025, 4:05 PM EST - 2 months ago

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

Nov 5, 2025, 10:03 AM EST - 3 months ago

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

Sep 29, 2025, 8:36 AM EDT - 4 months ago

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

Sep 24, 2025, 4:22 PM EDT - 4 months ago

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

Sep 23, 2025, 8:23 AM EDT - 4 months ago

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 6:13 PM EDT - 5 months ago

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

Sep 2, 2025, 8:22 AM EDT - 5 months ago

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 4:05 PM EDT - 6 months ago

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

Aug 7, 2025, 10:00 AM EDT - 6 months ago

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

Aug 6, 2025, 8:33 AM EDT - 6 months ago

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 31, 2025, 3:01 PM EDT - 6 months ago

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

Jul 22, 2025, 8:20 AM EDT - 7 months ago

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

Jul 16, 2025, 8:45 AM EDT - 7 months ago

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 10, 2025, 3:29 PM EDT - 7 months ago

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

Jul 8, 2025, 8:05 AM EDT - 7 months ago

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces Positive Nasdaq Listing Determination

Jul 2, 2025, 4:25 PM EDT - 7 months ago

SeaStar Medical Announces Positive Nasdaq Listing Determination

SeaStar Medical Reports Update on Nasdaq Listing Status

Jun 25, 2025, 8:05 AM EDT - 7 months ago

SeaStar Medical Reports Update on Nasdaq Listing Status

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

Jun 24, 2025, 9:05 AM EDT - 8 months ago

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

Jun 20, 2025, 12:10 PM EDT - 8 months ago

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research

Jun 11, 2025, 8:25 AM EDT - 8 months ago

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

May 28, 2025, 8:05 AM EDT - 8 months ago

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:49 PM EDT - 9 months ago

SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

May 14, 2025, 4:05 PM EDT - 9 months ago

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

May 13, 2025, 8:05 AM EDT - 9 months ago

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

May 7, 2025, 10:00 AM EDT - 9 months ago

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

Apr 30, 2025, 8:05 AM EDT - 9 months ago

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

Apr 8, 2025, 8:05 AM EDT - 10 months ago

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 27, 2025, 4:05 PM EDT - 11 months ago

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 24, 2025, 5:30 PM EDT - 11 months ago

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

Mar 18, 2025, 8:45 AM EDT - 11 months ago

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

Feb 3, 2025, 4:05 PM EST - 1 year ago

SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

Jan 22, 2025, 7:30 AM EST - 1 year ago

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

Jan 13, 2025, 8:30 AM EST - 1 year ago

FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

Jan 8, 2025, 8:30 AM EST - 1 year ago

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

Dec 23, 2024, 7:00 AM EST - 1 year ago

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

Dec 11, 2024, 6:30 AM EST - 1 year ago

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

Dec 4, 2024, 8:30 AM EST - 1 year ago

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024

Nov 26, 2024, 8:00 AM EST - 1 year ago

SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

Nov 22, 2024, 8:30 AM EST - 1 year ago

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

Nov 15, 2024, 8:30 AM EST - 1 year ago

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 13, 2024, 5:05 PM EST - 1 year ago

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

Oct 31, 2024, 8:30 AM EDT - 1 year ago

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

HuntingBenjmins
HuntingBenjmins Feb. 4 at 5:30 AM
$ICU Allright…who gave Nikki the fruit loops with sugar on them?
0 · Reply
josh77
josh77 Feb. 4 at 4:38 AM
$ICU 5. Expanded Indications If ICU announces that its technology can be applied to additional patient groups or conditions, the market size grows — and so does investor interest. 6. Real‑World Hospital Use Positive case studies or early adoption by hospitals could provide real‑world proof that the device works and has value.
0 · Reply
josh77
josh77 Feb. 4 at 4:38 AM
$ICU Catalysts for ICU This version digs deeper into what actually could move the stock. Detailed Catalyst Breakdown: For ICU, the most realistic catalysts fall into a few key categories: 1. Clinical Data Updates Any positive results from ongoing or upcoming studies would be the strongest catalyst. Even early‑stage improvements in safety or efficacy could shift sentiment. 2. FDA or Regulatory Progress If the company receives: acceptance of a submission Fast Track designation positive feedback from a regulatory meeting …that would immediately strengthen the outlook. 3. Strategic Partnerships A collaboration with a larger medical device or biotech company would: validate the technology bring in resources reduce financial pressure This is one of the most powerful potential catalysts. 4. Funding or Cash‑Runway Improvements Non‑dilutive funding, grants, or institutional investment would ease concerns about survival and delisting.
0 · Reply
josh77
josh77 Feb. 4 at 4:25 AM
$ICU If they can deliver positive clinical updates, secure a partnership, or make progress with the FDA, the sentiment could change quickly. Even stabilizing their finances or expanding indications would help. It’s definitely a high‑risk play, but in this sector, momentum can flip fast when the right pieces fall into place. I’m just watching for those potential catalysts and staying patient.
0 · Reply
Brad_7424
Brad_7424 Feb. 4 at 2:32 AM
$ICU Folks, this it was severe delusion looks like. $45 per share, yet their last announced revenue wasn't even enough to pay its staff a salary💀 This will go below 1 again and have another RS at the end of this year or early 2027. You might get lucky trading this short term, but that's gambling, not investing.
0 · Reply
hardgrandpa
hardgrandpa Feb. 4 at 1:02 AM
$ICU
0 · Reply
Yi_YandH
Yi_YandH Feb. 3 at 11:41 PM
$ICU When the pissants piss, Ich hüpfen vor freude!!!
0 · Reply
Nikki7220
Nikki7220 Feb. 3 at 11:13 PM
$ICU ***** Whatever you think, ICU does NOT have manpower to move SCD. Worst they NEVER know how to market SCD. They are so WEAK. Presentations to financial people so many times NOT attracting meaningful investors.
1 · Reply
techjerk
techjerk Feb. 3 at 10:54 PM
$ICU Who says a pessimist can't pump lol
0 · Reply
techjerk
techjerk Feb. 3 at 10:53 PM
$ICU Regulatory & Partnership News: Potential announcements regarding additional Breakthrough Device Designations or Humanitarian Use Designations to speed up commercialization in other indications, such as Cardio-Renal Syndrome.
0 · Reply
techjerk
techjerk Feb. 3 at 10:53 PM
$ICU NEUTRALIZE-AKI Trial Progress: Updates regarding the acceleration of enrollment for the adult Acute Kidney Injury (AKI) pivotal trial to meet the target of completing enrollment by late 2026.
0 · Reply
techjerk
techjerk Feb. 3 at 10:53 PM
$ICU QUELIMMUNE Commercial Adoption Updates: The company has targeted 2026 to double the number of top-ranked children's medical centers using its FDA-approved QUELIMMUNE for pediatric AKI, with updates expected on new site activations.
0 · Reply
techjerk
techjerk Feb. 3 at 10:52 PM
$ICU 2025 Fourth Quarter and Full Year Financial Results (Est. late March 2026): Based on previous schedules, earnings are anticipated around March 26, 2026, which will provide updates on cash runway and revenue growth.
0 · Reply
techjerk
techjerk Feb. 3 at 10:52 PM
$ICU Noble Capital Markets Emerging Growth Virtual Equity Conference (Feb 5, 2026): CEO Eric Schlorff is presenting on February 5, 2026, where further details on 2026 strategy are likely.
0 · Reply
richard52
richard52 Feb. 3 at 10:28 PM
$ICU Stock holding strong as we await release of new numbers. Thursday may be the day for surge for numbers release. Once SAVE registry complete it 8s plausible for talks on distribution/partnership to begin in ernest.
0 · Reply
Nikki7220
Nikki7220 Feb. 3 at 9:49 PM
$ICU **** This NEW CFO is a SCAPEGOAT for this SCAMMY CEO, he NEVER bought a share in 2 years.
1 · Reply
Nikki7220
Nikki7220 Feb. 3 at 9:46 PM
$ICU ***** The REAL PROBLEM with the current price = shareholders soooo WEAK. We must DEMAND everything be transparent. ICU KNOWS HOW TO MANIPULATE us the last 2 years.
0 · Reply
Nikki7220
Nikki7220 Feb. 3 at 9:36 PM
$ICU ***** ICU = a bunch of scientists WITHOUT marketers. Scientists = don't make money except salaries and bonusses on shareholder's sweat.
1 · Reply
Nikki7220
Nikki7220 Feb. 3 at 9:32 PM
$ICU ***** Cash on hand will be exhausted in few months and our shares will be on sales AGAIN. ICU must come up with a new strategy in 2 MONTHS.
1 · Reply
Nikki7220
Nikki7220 Feb. 3 at 9:27 PM
$ICU ***** Ask our CMO, Dr. Chung, when his bamboo tree would grow to 99 ft tall? He is wishing like his CEO said $4B TAM without saying WHEN?
0 · Reply
Nikki7220
Nikki7220 Feb. 3 at 9:19 PM
$ICU ***** I am willing to contribute a large money to investigate everything about ICU if the majority of shareholders in here willing.
2 · Reply
Nikki7220
Nikki7220 Feb. 3 at 9:15 PM
$ICU ***** Based on the last 2 years, our stock price should be over $45 today. ICU is being manipulated by someone and should be INVESTIGATED in due time. They've been keeping sharehokders GUESSING of their progress. The SECOND RS was a SCAM because they went ahead to PAY they salaries and bonuses before RS.
1 · Reply